Evidence check: CYP2D6 in the context of Fruchtbarkeit

CYP2D6 is a key phase I drug-metabolizing enzyme involved in the breakdown of many medications and endogenous substances, including steroid hormones. In the context of fertility, CYP2D6 is discussed mainly regarding its role in metabolizing estrogens, progestins, and SSRIs sometimes used in fertility treatments. However, evidence for a direct impact of CYP2D6 variants on fertility is weak. Some association studies suggest a possible role in hormone regulation, but effect sizes are small and results inconsistent. Clinical relevance for individual fertility outcomes is unclear. A DNA test for CYP2D6 cannot be recommended as a diagnostic or predictive tool for fertility issues. Established fertility assessments (hormone panels, cycle tracking, semen analysis) remain the standard. The evidence is mechanistic/pharmacogenetic, not based on direct fertility endpoints. Consumers should be cautious about overinterpreting such genetic results.